Premium
The role of hepatocyte nuclear factor 4α in regulating mouse hepatic anticoagulation and fibrinolysis gene transcript levels
Author(s) -
SAFDAR H.,
INOUE Y.,
VAN PUIJVELDE G. H.,
REITSMA P. H.,
VAN VLIJMEN B. J. M.
Publication year - 2010
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2010.04080.x
Subject(s) - hepatocyte nuclear factor 4 , hepatocyte nuclear factors , antithrombin , transcription factor , biology , fibrinolysis , microbiology and biotechnology , nuclear receptor , gene , medicine , genetics , heparin , biochemistry
1 Rai R, Regan L. Recurrent miscarriage. Lancet 2006; 368: 601–11. 2 Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, Scapin M, Arcaini L, Tezza F, Moratti R, Pascutto C, Fabris F, Morra E, Cazzola M, LazzarinoM. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 2007; 110: 485–9. 3 Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev 2008; 22: 235–45. 4 Baxter EJ, Scott LM, Campbell PJ, East C, Fo urouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–61. 5 Mercier E, Lissalde-Lavigne G, Gris JC. JAK2 V617F mutation in unexplained loss of first pregnancy. N Engl J Med 2007; 357: 1984– 5. 6 Dahabreh IJ, Jones AV, Voulgarelis M, Giannouli S, Zoi C, afakisTzannatos C, Varla-Leftherioti M, Moutsopoulos HM, Loukopoulos D, Fotiou S, Cross NC, Zoi K. No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage. Br J Haematol 2009; 144: 802–3. 7 Dutch Society of Obstetricians and Gynaecologists. Guideline: Recurrent Miscarriage. Utrecht, Netherlands: Dutch Society of Obstetricians and Gynaecologists, 1999. 8 Tefferi A, Vardiman JW. The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol 2007; 14: 115–22. 9 Rapado I, Albizua E, Ayala R, Hernandez JA, Garcia-Alonso L, Grande S, GallardoM,Gilsanz F,Martinez-Lopez J. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol 2008; 87: 741–9.